PICO Portalanswers from OpenAlex & ORCID
Shirish M. Gadgeel
ResearcherPublications, citations & collaboration network
Shirish M. Gadgeel is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Shirish M. Gadgeel have?
PICO Portalindexed works
Shirish M. Gadgeel has 859 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Shirish M. Gadgeel have?
PICO Portalcitation count
Shirish M. Gadgeel has 43,144 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Shirish M. Gadgeel?
PICO Portalh-index
Shirish M. Gadgeel has an h-index of 79 in OpenAlex.
What is the i10-index of Shirish M. Gadgeel?
PICO Portali10-index
Shirish M. Gadgeel has an i10-index of 293 in OpenAlex.
What is the ORCID of Shirish M. Gadgeel?
PICO Portalorcid
The ORCID for Shirish M. Gadgeel is on the source record.
What is the OpenAlex record for Shirish M. Gadgeel?
PICO Portalopenalex
The OpenAlex for Shirish M. Gadgeel is on the source record.
What are the most-cited papers on Shirish M. Gadgeel?
PICO Portalmost cited works
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Dómine, Philip R. Clingan, Maximilian J. Hochmair, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio‐Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M. Catherine Pietanza, Marina Chiara Garassino
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J. Hochmair, Philip R. Clingan, Steven Powell, Susanna Y. Cheng, Helge Bischoff, Nir Peled, Francesco Grossi, Ross Jennens, Martin Reck, Edward B. Garon, Silvia Novello, Belén Rubio‐Viqueira, Michael Boyer, Takayasu Kurata, Jhanelle E. Gray, Jing Yang, Tuba Öcek Baş, M. Catherine Pietanza, Marina Chiara Garassino
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer
Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo‐Jack, Shirish M. Gadgeel, Katherine R. Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba R. Digumarthy, Colleen L. Channick, Colleen Keyes, Gad Getz, Dora Dias‐Santagata, Rebecca S. Heist, Jochen K. Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw